Irritable bowel syndrome: zinc changes some markers, with no demonstrated sleep benefit

Changing blood markers does not mean sleeping better. In a randomized trial involving 84 people with irritable bowel syndrome, zinc, alone or combined with a probiotic, changed some indicators of oxidative stress. However, no significant between-group effect on sleep quality was observed. These results are available in a PubMed abstract; the full text was not consulted.

Illustration of tablets and capsules next to a diagram of the intestine.
SupplementsEditorial illustration, not study data.

Three groups followed for 90 days

The researchers assigned participants to three groups: zinc with a probiotic placebo, zinc with a probiotic, or two placebos. This randomized, parallel-group trial was double-blind and lasted 90 days.

Measurements included blood zinc, several markers of oxidative stress, and sleep quality. The abstract reports the use of validated methods but does not specify which sleep questionnaire was used. It also mentions registration with the Iranian Registry of Clinical Trials.

Biological changes, but not across all outcomes

Compared with placebo, both groups receiving zinc showed an increase in blood zinc and a decrease in total oxidant status, known as TOS, and the oxidative stress index, known as OSI.

However, no significant between-group differences were observed in total antioxidant capacity, malondialdehyde, or superoxide dismutase activity, other indicators studied. The findings therefore do not show a uniform improvement across all markers.

Sleep quality also showed no significant between-group difference. This does not prove that an effect is impossible, but this trial does not demonstrate a benefit for this outcome.

No established additional benefit from the probiotic

The abstract reports changes in both groups receiving zinc but does not present a comparison demonstrating that the zinc–probiotic combination was superior to zinc alone. It therefore does not support the conclusion that adding the probiotic offers an advantage.

Intestinal barrier integrity and microbiome modulation provide the biological context put forward by the authors. On their own, they do not prove that this supplementation improves sleep or digestive symptoms. The abstract does not report findings on improvement in these symptoms.

What this trial tells us

The findings concern people with irritable bowel syndrome, not a general population seeking better sleep. The authors themselves emphasize that the clinical relevance of the biological changes remains to be confirmed.

For a purchasing decision, the distinction is clear: this trial provides a signal for some blood markers, but no demonstrated justification for taking zinc or a zinc–probiotic combination to improve sleep.

Limitations to keep in mind

Only the PubMed abstract was consulted. The sample comprised 84 participants, with 90 days of follow-up. The information provided does not allow verification of the probiotic's composition, adverse effects, dropouts, funding, or conflicts of interest. Changes in biomarkers do not demonstrate clinical improvement and cannot be extrapolated to a healthy population.

What we can take away

In this trial, zinc changes some biological markers without a demonstrated sleep benefit. The clinical value and any potential advantage of the probiotic remain to be established.

Sources and provenance

Partager cet article

X f in

An error or a source to report? Contact the editorial team.